Left ventricular assist devices (LVADs) and total artificial hearts (TAHs) are surgically
implanted as permanent treatment of unrecoverable heart failure. Both LVADs and TAHs are …

Successful practice of cardiovascular medicine requires familiarity with the complex ethical
issues that accompany therapeutic innovation and diffusion. Even as technologies transition …

Abstract Purpose of Review Although the utilization of mechanical circulatory support (MCS)
devices is increasing, ethical dilemmas regarding device deactivation and dying process …

Background Beliefs around deactivation of a left ventricular assist device (LVAD) vary
substantially among clinicians, institutions, and patients. Therefore, we sought to understand …

Left ventricular assist devices (LVADs) have become an increasingly common advanced
therapy in patients with severe symptomatic heart failure. Their unique nature in prolonging …

Background: Left ventricular assist devices (LVADs) are a relatively new technology that is
increasingly used to preserve cardiac function. These devices work by a mechanism that …

More than 23 million adults worldwide have heart failure (HF). Although survival after heart
failure diagnosis has improved over time, mortality from heart failure remains high. At the …

The use of mechanical circulatory support (MCS) devices has increased sixfold since 2006.
Although there is an established legal and ethical consensus that patients have the right to …

Durable left ventricular assist devices (LVADs) have consistently demonstrated utility in
improving survival in patients with end-stage heart failure. 1 Ongoing use of LVADs, along …

BACKGROUND Trial and registry data have reported mortality rates and causes of death in
patients with left ventricular assist devices (LVADs); however, a more granular description is …